The openFDA Drugs@FDA record for BLA 761458 tracks one of the newer biologics in the respiratory-inflammation space: GSK's EXDENSUR, the brand name for depemokimab-ulaa, a 100 mg injectable monoclonal antibody. What stands out in the record is the cadence. The original biologics license application (ORIG-1) was approved on 16 December 2025, classified Type 1 — New Molecular Entity. Barely six months later, the application already carries an approved labeling supplement (SUPPL-2, class LABELING, status AP). For a brand-new biologic, that is a fast first label update — the regulatory signature of an active launch rather than a product left to settle.
Two technical details in the record are worth decoding for readers who treat therapeutics as assets. First, the -ulaa suffix: that is the FDA's nonproprietary-name suffix convention for biologics, a four-letter, meaningless-by-design appendage attached to the core name (depemokimab) to make each biologic and its future biosimilars individually identifiable in pharmacovigilance and substitution. The presence of that suffix tells you immediately this is a biologic licensed under a BLA, not a small molecule under an NDA. Second, the -mab stem in 'depemokimab' marks it as a monoclonal antibody. Together the naming tells you the modality before you read a single clinical detail: a licensed monoclonal antibody biologic.
What depemokimab targets, and why 'long-acting' is the pitch
Depemokimab belongs to the anti-IL-5 class — biologics that neutralize interleukin-5, the cytokine that drives the maturation, recruitment, and survival of eosinophils. Eosinophils are the white blood cells central to type-2 inflammatory disease, most prominently severe eosinophilic asthma and related eosinophil-driven conditions. The anti-IL-5 mechanism is well validated commercially; GSK already pioneered the class. Depemokimab's differentiation is engineering for an unusually long duration of action — the kind of antibody half-life that supports very infrequent dosing, the marquee feature GSK has built the asset's positioning around.
The business case for a long-acting respiratory biologic is dosing convenience as a competitive weapon. In a crowded biologic category where multiple anti-IL-5 and anti-IL-5-receptor agents already compete, a meaningfully longer dosing interval is a differentiator that drives adherence, reduces injection burden, and gives payers and prescribers a reason to choose one antibody over another. For a chronic disease managed over years, fewer injections per year is a real value proposition, not a marketing flourish. That is the strategic logic behind GSK developing yet another entrant in a class it already leads — extend the franchise with a next-generation dosing profile rather than cede the next round of competition.
Reading a six-month labeling supplement
So what does the early SUPPL-2 represent? The record gives its class (labeling) and status (approved) but not the changed text, which is standard. A labeling supplement this soon after launch typically reflects one of a few things: incorporation of additional clinical data, a refinement of the prescribing information as the product moves into commercial use, an indication or population adjustment, or safety-language updates. The key point is interpretive discipline — this is a labeling supplement, not a new molecular entity or a new BLA, so it does not by itself expand the universe of approved products. What it does is keep a freshly launched biologic's official profile current and competitive while GSK builds the commercial base.
The pattern matters more than the single filing. A biologic that generates an approved labeling supplement within six months of original approval is one the sponsor is actively working — feeding new data into the label, sharpening the commercial proposition, and keeping the regulatory dossier in step with the launch. Compare that to a product whose record goes quiet after approval. The openFDA submission history is one of the clearest public proxies for which interpretation applies, and here it points to active management.
The franchise frame
For GSK, depemokimab is best understood as a franchise-extension asset in respiratory inflammation, a therapeutic area where the company has decades of incumbency and an installed base of prescribers. Launching a long-acting anti-IL-5 antibody lets GSK defend that territory against both its own maturing products and competitors' offerings, and it gives the company a next-generation dosing story to carry the franchise forward. A new molecular entity approval in December 2025 is the heavy event; the labeling supplement six months later is the lighter, confirming one — evidence that the launch is being tended rather than parked.
The honest read of the openFDA record is therefore layered. The headline event already happened: a Type 1 new molecular entity, a brand-new biologic, cleared in late 2025. The June 2026 filing is a labeling supplement, operationally meaningful but not market-expanding on its own. The signal worth carrying forward is the tempo — a major respiratory player bringing a long-acting biologic to market and immediately keeping its label moving. In therapeutics-as-an-asset terms, that is what the early innings of a defended franchise extension look like, and the Drugs@FDA record for BLA 761458 is where the early box score is kept.
The biosimilar clock starts now
There is a longer-horizon reason the naming convention on EXDENSUR matters, and it speaks to how biologics are valued. The very existence of the four-letter suffix is the regulatory system bracing for a future in which depemokimab faces biosimilar competition. Biologics, unlike small molecules, are not exactly reproducible — a biosimilar is a highly similar but not identical version — and the suffix exists so that, years from now, depemokimab-ulaa and any biosimilars of it can be told apart in prescribing and safety tracking. For a drug approved in December 2025, that competition is far off, but the clock on exclusivity begins at approval. The window in which GSK has the long-acting anti-IL-5 antibody essentially to itself is exactly the window in which it must establish the product, generate the label-expanding data, and lock in prescriber habits.
That reframes why the early activity on the application matters. The labeling supplement six months after launch, the active maintenance of the dossier, the differentiated long-acting dosing pitch — all of it is GSK working to build durable share during the protected window. A respiratory incumbent does not bring a next-generation biologic to market casually; it does so to defend a franchise it already leads against both its own aging products and rivals. The openFDA record captures only the regulatory mechanics, but those mechanics are the visible surface of a deliberate, time-sensitive commercial strategy, and BLA 761458 is the public file where that strategy's early moves are recorded.